Investor Relations

Corporate Overview

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. To learn more, please visit www.VIZZ.com.

Latest Financial Results

Q2 2025

Quarter Ended Jun 30, 2025

News Icon

Latest News

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Events Icon

Upcoming Event

Citi’s 2025 BioPharma Back to School Conference

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449

Connect With Us